Main Figures and Tables

Slides:

Advertisements

Similar presentations

P449. p450 Figure 15-1 p451 Figure 15-2 p453 Figure 15-2a p453.

Advertisements

Technische Universität München Cancer biomarker discovery by chemical and quantitative proteomics Sebastian Berger, B. Sc., Center of Life and.

Gene Expression Signatures for Prognosis in NSCLC, Coupled with Signatures of Oncogenic Pathway Deregulation, Provide a Novel Approach for Selection of.

Primary Mets Node Patient 1Patient 2Patient 3 Primary Mets Node Patient 1Patient 2Patient 3 Primary Mets Node Patient 1Patient 2Patient 3 Primary Mets.

© 2005 Prentice Hall Inc. / A Pearson Education Company / Upper Saddle River, New Jersey Lung Cancer and Gefitinib  Lung cancer statistics in the.

2015/ NON-SMALL CELL LUNG CANCER (NSCLC) 1.1 Adenocarcinomas are often found in an outer area of the lung. 1.2 Squamous cell carcinomas are usually.

Healthy ControlCase 2D gel images of Serum protein sample Set of gel images for analysis.

Supplementary Figure 2: Representative Kaplan-Meier plots of overall survival considering alterations erbB signaling pathway genes and p53 in lung cancer.

Main Figures and Tables. Figure 1 Strategy (shall we make a strategy figure here?? ）

Supplemental Figure 1 Expression of UHRF1 detected by TaqMan qRT-PCR and many characteristics of patients were compared by Mann-Whiteney’s U-test. A. Expression.

Supplementary Figure 1: Correlation analysis of DKC1 mRNA and dyskerin protein quantity in neuroblastoma cell lines.

Preliminary data of Non- Small Cell Lung Cancer gene expression pilot study Tõnu Vooder, Kristjan Välk, Andres Metspalu Genoa 2005.

Figure S1. A B C Survival probability (%) P = 0.21 P = 0.37 P = 0.12

Supplementary Figure 1. Importance of first neighbours in breast cancer, hepatocellular carcinoma and non-small cell lung cancer in the SignaLink network.

Silvestri Gerard A. , MD, FCCP, Rivera M. Patricia , MD, FCCP CHEST

Overexpression of β-Catenin and Cyclin D1 is Associated with Poor Overall Survival in Patients with Stage IA–IIA Squamous Cell Lung Cancer Irrespective.

Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.

Fig. 2. High-resolution melting curves for exon 21 of the EGFR gene

Lung squamous cell carcinoma

Volume 18, Issue 6, Pages e1 (November 2017)

Hallett, et al., - Supplementary Figure 1

Prognosis of younger patients in non-small cell lung cancer

Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.

Volume 18, Issue 13, Pages (March 2017)

RNA Sequencing Approaches to Identify Novel Biomarkers for Venous Thromboembolism (VTE) in Lung Cancer Tamara A. Sussman MD1, Mohamed Abazeed MD PhD1,

EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma Maria I. Toki, MD,

Strategy Description Discovery Validation Application

Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.

Lu Chen, PhD, Brienne E. Engel, PhD, Eric A. Welsh, PhD, Sean J

Kenneth G. Geles, Wenyan Zhong, Siobhan K

Antiproliferative effects of erlotinib correlate poorly with abundance of p-EGFR. Antiproliferative effects of erlotinib correlate poorly with abundance.

Volume 10, Issue 9, Pages (March 2015)

A Novel Classification of MUC1 Expression Is Correlated with Tumor Differentiation and Postoperative Prognosis in Non–Small Cell Lung Cancer Shinjiro.

Figure 2 The association between CD8+ T‑cell density of the tumour

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Significance of P53 and Rb protein expression in surgically treated non-small cell lung cancers Yung-Chie Lee, MD, PhD, Yih-Leong Chang, MD, Shi-Ping.

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Fig. 8. Gene and protein changes in ALK-dependent STING pathways in human sepsis. Gene and protein changes in ALK-dependent STING pathways in human sepsis.

EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with Chemotherapy Michele.

A Pilot Characterization of Human Lung NSCLC by Protein Pathway Activation Mapping Angela Zupa, BS, Giuseppina Improta, BS, Alessandra Silvestri, PhD,

Apoptosis-targeted therapies for cancer

Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.

Membrane Carbonic Anhydrase IX Expression and Relapse Risk in Resected Stage I–II Non–Small-Cell Lung Cancer David J. Stewart, MD, Maria I. Nunez, MD,

Meta-analysis of all patients

Deletion of Lats1 is phenotypically distinct from Lats2 deletion in PyMT tumors. Deletion of Lats1 is phenotypically distinct from Lats2 deletion in PyMT.

Invasive adenocarcinoma with bronchoalveolar features: A population-based evaluation of the extent of resection in bronchoalveolar cell carcinoma Bryan.

Refer to word document for this table

High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer Heounjeong Go, MD, Yoon Kyung Jeon, MD, PhD, Hyo Jin.

Differential gene expression in whole blood from SJIA patients and healthy controls. A. Data were normalized in Beadstudio using the "average" method and.

Apoptosis-targeted therapies for cancer

Significant differences in translational efficiencies of DNA damage repair pathway genes between patient clusters. Significant differences in translational.

C-MET/Phospho-MET Protein Expression and MET Gene Copy Number in Non-small Cell Lung Carcinomas Koji Tsuta, MD, PhD, Yoshiki Kozu, MD, PhD, Takahiro.

Expression of Signaling Mediators Downstream of EGF-Receptor Predict Sensitivity to Small Molecule Inhibitors Directed Against the EGF-Receptor Pathway

Overview of sample and patient characteristics for 444 tumors from 429 patients with mCRPC. Overview of sample and patient characteristics for 444 tumors.

Supplementary Figure S1

Thymidylate Synthase Protein Expression by IHC and Gene Copy Number by SISH Correlate and Show Great Variability in Non–Small Cell Lung Cancer Murry.

Figure S1. A. B. Figure S1. Kaplan-Meier curve of progression-free survival by treatment group in soluble heregulin (HRG)-high population (A) and soluble.

CHCHD2 and EGFR protein expression in NSCLC

Greater induction of apoptosis following EGFR TKI treatment correlates with higher basal BIM expression across a panel of EGFR-mutant lung cancers. Greater.

c-Raf in KRas Mutant Cancers: A Moving Target

EN1 expression in breast cancer and clinical outcome.

Pancreatic adenocarcinoma, chronic pancreatitis, and normal pancreas samples can be distinguished on the basis of gene expression profiling. Pancreatic.

Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.

Identification of general and tissue-specific essential genes.

Reduced expression of the tumor suppressor PTEN occurs in tumors with both squamous cell and adenocarcinoma histology. Reduced expression of the tumor.

Summary of the experimental strategy and key findings of Mitra and colleagues (10). Summary of the experimental strategy and key findings of Mitra and.

Supplementary Table 2. Antibodies and conditions used for the IHC studies.

Fig. 1. FAM83H over-expression is associated with poor prognosis of CC

ENTPD5 expression correlates with EGFR and activated AKT levels in human NSCLC. A, percentages of PTEN-low lung adenocarcinoma cases with at least one.

DO NOT POST #4054 Gene expression Difference (GED) Revealed Immune Function Gene UP- or Down-regulation as Tumor-associated Inflammatory Cell (TAIC) Infiltration.

Presentation transcript:

Main Figures and Tables

Figure 1 Strategy (shall we make a strategy figure here??）

Need to replaced by the final figures samples a b proteins a) Sample-sample correlation plot using all the quantified kinases; b) clustering analysis of samples based on the differential expressed kinase; C) Supervised cluster analysis ZW: we can cut the samples labels control cancer Need to replaced by the final figures high low

Figure 3. Signaling pathway analysis of the differential proteins (pathway will be generated either by IPA or KEGG)

Table 1. Descriptive characteristics of the patients with NSCLC

Figure 4.

Figure 5. DAPK2 MELK MELK in Adenocacinoma MELK in Squamouse cell carcinoma

Table 2. Correlation analysis

Supplementary Figures

Supplementary Figure S1 – PCA Analysis B C cancer cancer control proteins control PCA on samples with p<0.05 PCA on samples without any filter PCA on proteins with p<0.05

Squamouse cell carcinoma Supplementary Figure S2 EGFR Adenocarcinoma Squamouse cell carcinoma P = 0,006231 P = 0,03599 high expression Overall Survival Probability low expression Overall Survival [months] 0 50 100 150 200 0.0 0.2 0.4 0.6 0.8 1.0

Adenocarcinoma & Squamouse cell carcinoma Supplementary Figure S3 DAPK2 a. Adenocarcinoma & Squamouse cell carcinoma P = 0,008825 low expression (n=45) high expression (n=275) Overall Survival Probability 0 50 100 150 200 Overall Survival [months] 0.0 0.2 0.4 0.6 0.8 1.0

Squamouse cell carcinoma DAPK2 b. c. Adenocarcinoma Squamouse cell carcinoma low expression (n=33) 0.0 0.2 0.4 0.6 0.8 1.0 Overall Survival Probability 0.0 0.2 0.4 0.6 0.8 1.0 low expression (n=12) P = 0,0198 high expression (n=113) P = 0,03282 high expression (n=162) 0 50 100 150 200 Overall Survival [months] 0 50 100 150 200 Overall Survival [months]

Adenocarcinoma & Squamouse cell carcinoma Supplementary Figure S4 MELK a. Adenocarcinoma & Squamouse cell carcinoma P = 0,043 low expression (n=68) high expression (n=291) Overall Survival Probability 0 50 100 150 200 Overall Survival [months] 0.0 0.2 0.4 0.6 0.8 1.0

Squamouse cell carcinoma MELK b. c. Adenocarcinoma Squamouse cell carcinoma 0.0 0.2 0.4 0.6 0.8 1.0 0.0 0.2 0.4 0.6 0.8 1.0 0.0 0.2 0.4 0.6 0.8 1.0 Overall Survival Probability low expression (n=28) low expression (n=40) P = 0,69 P = 0,017 high expression (n=153) high expression (n=139) 0 50 100 150 200 Overall Survival [months] 0 50 100 150 200 Overall Survival [months] Overall Survival [months]

Squamouse cell carcinoma DDR1 b. c. Adenocarcinoma Squamouse cell carcinoma 0.0 0.2 0.4 0.6 0.8 1.0 0.0 0.2 0.4 0.6 0.8 1.0 high expression (n=20) Overall Survival Probability high expression (n=54) low expression (n=29) P = 0,0485 P = 0,7228 moderate expression (n=100) low expression (n=157) 0 50 100 150 200 Overall Survival [months] 0 50 100 150 200 Overall Survival [months] Overall Survival [months] Overall Survival [months]